Collagen-based drug maker Innocoll files for an $86 million IPO

By Renaissance Capital,

Shutterstock photo

Innocoll, which develops and markets collagen-based products to treat adhesions, pain and foot infections filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The company lists Morgan Stanley ( MS ) among its investors, with a 24% pre-IPO stake.

The Athlone, Ireland-based company, which was founded in 1997 and booked $5 million in sales for the 12 months ended March 31 2014, plans to list on the NASDAQ under the symbol INNL. Innocoll initially filed confidentially on March 26, 2014. Piper Jaffray and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: MS

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by